Poster
Champions' Latest Poster
An Integrated Preclinical Platform for Antibody-Drug Conjugate Development
Summary
Our latest study demonstrates how a multi-omic strategy, coupled with functional validation, identifies tumor-selective ADC targets and refines therapeutic windows across diverse cancer indications.
Key Takeaways
Target identification through Lumin multi-omics
Integration of transcriptomic and proteomic profiling across >1,500 PDXs and 70+ cancer cell lines.
Differential expression validation
Comparative analysis of tumor vs. normal tissue using GTEx data to ensure minimal off-target toxicity.
Functional characterization
Isogenic cell lines and internalization assays confirm target specificity and payload activity.
Ex vivo efficacy testing
TumorGraft3D organoid models preserve patient tumor heterogeneity, enabling accurate ADC response prediction.
In vivo confirmation
NK adoptive transfer models evaluate antibody-dependent cellular cytotoxicity (ADCC) under immune-relevant conditions.
Case example
Identification of “Target-1,” a novel ADC target with limited normal tissue expression and patient-specific response patterns in colorectal PDXs.
Clinical insight
Variability in ADC sensitivity underscores the importance of matching payload, target, and patient biology early in development.
Translational advantage
Integrates discovery, validation, and functional testing into one streamlined workflow, accelerating next-generation ADC programs.
Comprehensive pipeline
From in silico target mining to ex vivo/in vivo efficacy, Champions delivers a complete preclinical continuum.